Mutation of *Mycobacterium tuberculosis* and Implications for Using Whole-Genome Sequencing for Investigating Recent Tuberculosis Transmission

Kristin N. Nelson 1*, Sarah Talarico 2, Shameer Poonja 3, Clinton J. McDaniel 2, Martin Cilnis 4, Alicia H. Chang 3, Kala Raz 2, Wendy S. Noboa 3, Lauren Cowan 2, Tambi Shaw 4, James Posey 2 and Benjamin J. Silk 2

Tuberculosis (TB) control programs use whole-genome sequencing (WGS) of *Mycobacterium tuberculosis* (Mtb) for detecting and investigating TB case clusters. Existence of few genomic differences between Mtb isolates might indicate TB cases are the result of recent transmission. However, the variable and sometimes long duration of latent infection, combined with uncertainty in the Mtb mutation rate during latency, can complicate interpretation of WGS results. To estimate the association between infection duration and single nucleotide polymorphism (SNP) accumulation in the Mtb genome, we first analyzed pairwise SNP differences among TB cases from Los Angeles County, California, with strong epidemiologic links. We found that SNP distance alone was insufficient for concluding that cases are linked through recent transmission. Second, we describe a well-characterized cluster of TB cases in California to illustrate the role of genomic data in conclusions regarding recent transmission. Longer presumed latent periods were inconsistently associated with larger SNP differences. Our analyses suggest that WGS alone cannot be used to definitively determine that a case is attributable to recent transmission. Methods for integrating clinical, epidemiologic, and genomic data can guide conclusions regarding the likelihood of recent transmission, providing local public health practitioners with better tools for monitoring and investigating TB transmission.

Keywords: tuberculosis—epidemiology, prevention and control, genomic sequencing, tuberculosis transmission, public health practice
INTRODUCTION

Tuberculosis (TB) control programs use molecular characterization and surveillance of *Mycobacterium tuberculosis* (*Mtb*) for detecting TB case clusters, indicating or refuting possible epidemiologic links between patients, and defining an outbreak's magnitude and scope (1). Genotyping can also provide evidence that cases are attributable to recent TB transmission vs. reactivation of latent *Mtb* infection that was acquired during the remote past. Operationally, US TB programs often define recent transmission as an infection acquired during the previous 2 years (2), although no standard definition exists. Cases attributed to recent transmission are a priority for public health intervention because they can indicate existence of previously unrecognized infectious TB source cases or instances where contacts were not successfully identified or the evaluation for or treatment of TB infection was not completed. Genotyping based on a combination of spacer oligonucleotide typing (spolotyping) and 24-locus mycobacterial interspersed repetitive unit–variable number tandem repeat (MIRU-VNTR) is performed for all culture-confirmed TB cases in the United States and is used to identify genotype-matched clusters (1). During 2012, the US Centers for Disease Control and Prevention’s (CDC) Division of Tuberculosis Elimination (DTBE) began selectively performing whole-genome sequencing (WGS) for investigating clusters of genotype-matched TB cases for which recent transmission was suspected. As of 2018, CDC began prospectively performing WGS for all culture-confirmed TB cases in the United States, and clusters detected by genotyping now undergo rapid genomic characterization (3).

WGS can be used for identifying single nucleotide polymorphisms (SNPs) that distinguish *Mtb* isolates in a genotype-matched cluster. SNPs are mapped on a phylogenetic tree that diagrams the evolutionary direction of SNP accumulation among the isolates relative to a most recent common ancestor (MRCA), a hypothetical reference point from which all isolates in a given analysis are descended. The genetic distance between isolates is estimated by the number of SNPs between them, which provides a measure of their genetic relatedness. *Mtb* accumulates mutations slowly relative to other pathogens, but quickly enough that accumulation of SNPs can be observed over time. During TB disease, the *Mtb* genome has been estimated to acquire mutations at an average rate of 0.2–0.5 SNPs/genome/year, but this rate varies on the basis of characteristics of the infected person and the particular *Mtb* strain (4–7) (of note, the mutation rate and the substitution rate are distinct: the mutation rate reflects changes in the genome sequence between a parent and its offspring, or between isolates of cases that may be linked through transmission, whereas the substitution rate represents only those mutations that persist over time in the face of selection pressure). On the basis of DTBE’s previous experiences using WGS and phylogenetic analysis for investigating recent transmission as well as numerous reports in the published literature (8–14), isolates that differ by >10 SNPs can usually be considered unlikely to be the result of transmission that occurred within the preceding 2 years (i.e., recent transmission). As SNP distances provide strong, although not definitive, evidence of recent transmission, local US TB programs commonly use a threshold approach, whereby cases with isolates that differ by ≤5 SNPs are prioritized for epidemiologic investigation.

Interpreting pairwise SNP differences by using a threshold approach should be done cautiously in light of TB’s natural history, which is characterized by long and variable periods of latent infection. Concluding that a recent transmission event occurred between two persons can often depend on a key assumption regarding how quickly the *Mtb* genome accumulates mutations during latent infection. If we assume that this rate is similar to that during disease, we might expect *Mtb* sampled from a patient who had a long period of latent infection to have accumulated many SNPs relative to the isolate of the source patient from whom infection was acquired. If the mutation rate is slower during latent infection than during disease, we might expect little or no genomic change from the source patient’s *Mtb* isolate to that of the secondary patient. In this scenario, interpretation of closely related isolates in the phylogenetic analysis is more uncertain, and sequencing results alone might not help resolve whether an infection was recently or remotely (>2 years prior) acquired. To illustrate, we provide a hypothetical but realistic example (Figure 1). In this hypothetical scenario, a TB control program is using phylogenetic analysis results to help determine if isolates from two patients reported during 2020 are likely attributable to recent transmission. Interpretation of results may depend on whether the *Mtb* mutation rate is assumed to be similar during latency as during disease or to be slower.

To date, extant literature regarding the *Mtb* mutation rate during latent infection has been limited and inconsistent (Appendix Table 1). The increasing availability of WGS data in the United States, combined with epidemiologic data from TB cluster investigations conducted by state and local TB programs, provide a rich data source for examining mutation rates during latent *Mtb* infection. First, we selected a series of well-characterized TB case clusters in which epidemiologic data provided strong support for linking source and secondary cases. We estimated the length of the secondary case’s TB infection and examined the relationship between the duration of infection and accumulation of SNPs in the *Mtb* genome. Second, we describe a specific outbreak to illustrate the role and challenges of using genomic data for guiding conclusions regarding recent transmission in a programmatic setting. Our overarching goal is to help guide interpretation of SNP differences and improve TB programs’ understanding of the genomic evidence required for reaching conclusions regarding recent TB transmission in such settings of low TB incidence as the United States.

MATERIALS AND METHODS

Aggregated Cluster Data

For inclusion in our study, we considered all genotype-matched clusters of *Mtb* identified by molecular surveillance during 2015–2018 in Los Angeles County, California, that had ≥3 TB cases plus selected 2-case clusters for which transmission was suspected based on available epidemiologic information. A genotype match was defined on the basis of a combination
A hypothetical neighbor-joining tree (phylogenetic analysis) representing the genetic distances in single nucleotide polymorphisms (SNPs) among 15 isolates of Mycobacterium tuberculosis (Mtbc) from culture-confirmed tuberculosis cases reported during 2010–2020. Isolates are displayed as circles called nodes; isolates with the same genome sequence are displayed together in one node. Lines between nodes are labeled with the number of SNPs (mutations at a single position in the DNA sequence), and these lines are proportional in length to the number of SNPs. The most recent common ancestor (MRCA) is a hypothetical genome (not an actual isolate) from which all isolates in the phylogenetic analysis are descended. The MRCA serves as a reference point for examining the direction of genetic change. In this hypothetical scenario, a TB control program is using these phylogenetic analysis results to help determine if isolates from two patients reported during 2020 (shaded in gray) are likely attributable to recent transmission. If so, those cases are a priority for further investigation. Interpretation of these results, depending on if the Mtbc mutation rate is assumed to be similar during latency or to be slower, is as follows: Case 1 is unlikely to be involved in recent transmission under either assumption because the patient's isolate is genetically distant to that of the patient in Case 2 and all other cases in the analysis (≥19 SNPs). This interpretation might change as new cases are reported and added to the phylogenetic analysis. Case 2 is more challenging to interpret: under an assumption that Mtbc mutates at a similar rate during latent infection and disease, Case 2 is likely to be involved in recent transmission because the patient's isolate is genetically close to those of other cases in the analysis (0–2 SNPs). If Case 2 was attributable to reactivation after Mtbc infection during the remote past, more SNPs can be expected. Under an assumption that Mtbc mutates at a slower rate during latency than disease, Case 2 might be involved in recent transmission or attributable to reactivation after Mtbc infection during the remote past because relatively few SNPs are expected to accumulate during latency. Other clinical and epidemiologic data are needed for making a determination.
of death, if applicable. Briefly, the strength of an epidemiologic link between a pair of patients was defined as (a) definite (e.g., a named contact to another patient during the TB infectious period); (b) probable (e.g., an association with the same location during or at the approximate time when one patient had infectious TB); or (c) possible (e.g., two patients lived or worked in the same neighborhood during the same general period (Appendix Table 2). We excluded pairs for which the WGS and phylogenetic analysis results were available before the source patient was designated, so that all source patient determinations were independent of WGS data. We compiled into a data set source and secondary patients identified by local public health staff, by using information regarding the estimated timing of epidemiologic links and clinical indicators of infectiousness. We refer to this data set as the aggregated clusters, because this group includes source–secondary case pairs from all the genotype-matched clusters.

**Single-Cluster Data**

Separately, we also examined a single genotype-matched cluster of TB cases reported over the course of a 17-year period (2001–2017). Thirteen cases with this genotype were reported nationally, 10 of which were in California. An epidemiologic investigation of this California cluster identified 4 presumed source–secondary case pairs and a possible epidemiologic link for a fifth case. These cases were associated with a patient with infectious TB who had attended a California school during 2001.

**WGS and Phylogenetic Analysis**

WGS was performed for *Mtb* isolates from the investigated cases, and whole-genome SNP comparison for all source–secondary case pairs for which sequence data were available and 10 isolates from California with matching genotype as part of the single-cluster investigation. Briefly, *Mtb* DNA were extracted using the Quick-DNA Fungal/Bacterial Kit (Zymo Research Corp., Irvine, CA, USA), and 1 ng was used to prepare sequencing libraries by using the NexteraXT Kit (Illumina, San Diego, CA, USA) according to the package insert. Libraries were sequenced on an Illumina MiSeq instrument to generate 250-bp paired-end reads. All analyses of WGS data were performed by using BioNumerics 7.6.3 (Applied Maths, Sint-Martens-Latem, Belgium). Reference guided assemblies were created using Bioinformatics 7.6 Reference Mapper v 1.2.3 using *M. tuberculosis* strain H37Rv (NC009623) as the reference with the following settings for base calling: minimum total coverage = 3, minimum forward coverage = 1, minimum reverse coverage = 1, single base threshold = 0.75, double base threshold = 0.85, triple base threshold = 0.95, and gap threshold = 0.5. Average depth of coverage across the genome ranged from 42 to 222 with a median of 92. A list of high-quality, informative SNPs for each cluster was produced using the Strict SNP filtering (Closed SNP set) SNP analysis template for SNP filtering within the BioNumerics 7.6.3 software. For a SNP to be retained in the comparison, the base in all samples must have a total coverage of 5 reads, it must not be within 12 basepairs of another SNP, and it must not contain ambiguous bases, unreliable bases, or gaps. SNPs that are non-informative (identical in all samples) were also excluded. No genomic regions were specifically excluded from the analysis. For the single-cluster investigation, we constructed a phylogenetic tree by using the neighbor-joining method. Placement of the most recent common ancestor (MRCA) for isolates included in the phylogenetic tree was determined by rooting the tree with *Mtb* H37Rv as the outgroup.

**Statistical Analyses**

We aimed to estimate the duration of *Mtb* infection for the secondary patient, representing the time during which SNPs that differentiate the source patient's and secondary patient's isolates are expected to accumulate in the *Mtb* genome. To approximate this period, we calculated a case-pair interval to estimate the time difference between sample collection dates for the source–secondary case pairs in the aggregated cluster data (Figure 2). The case-pair interval is easy to calculate because the sample collection date is almost always available in case reports of culture-confirmed TB and is similar to the duration of *Mtb* infection among secondary patients as long as their infection occurred soon before the source patient's TB diagnosis. However, this interval is a poor proxy of infection duration if infection in the secondary patient occurred closer to the start of the TB infectious period for the source patient. To account for this, we also calculated a modified case-pair interval, which we defined as the time between the midpoint of the source patient's estimated TB infectious period and the sample collection date for the secondary patient (Figure 2). Of note, five case-pair intervals and two modified case-pair intervals were negative, indicating that the secondary patient received a diagnosis before the first patient; we reset these intervals to zero. We could not calculate a case-pair interval for two source cases with missing sample collection dates (i.e., excluded from Figure 4). SNP differences and these intervals were characterized by using median and interquartile ranges (IQRs).

We examined the associations between case-pair and modified case-pair intervals and SNP differences between each source–secondary case pair to determine if shorter intervals were linked with smaller pairwise SNP differences. We compared SNP differences between case pairs with modified case-pair intervals of ≤2 years, which we defined as recent TB transmission. We assessed multiple mathematical functions to determine which, if any, best fit these data. First, we fit a constant linear function, which assumes that *Mtb* accumulates SNPs at a constant rate throughout latent infection and disease. We also fit a piecewise linear function assuming that the mutation rate during disease might be different from the mutation rate during latent infection. We defined a threshold below which the modified case-pair interval was unlikely to include a long period of latent infection, equivalent to the sum of half the median TB infectious period of included source patients and the median TB infectious period of secondary patients. Secondary patients in pairs with an interval shorter than this period are presumed to have experienced short or no period of latent infection. As such, we assumed their *Mtb* isolates were subject only to the rate of mutation during disease. Secondary patients among pairs with an interval greater than
that threshold value likely experienced at least some period of latent infection, and we therefore assumed their Mtb isolates were subject to a composite of the mutation rates during disease and latent infection.

This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy; the Los Angeles County Department of Public Health’s Institutional Review Board also provided a non-research determination. Analysis code is available at https://github.com/kbratnelson/ltbi-mutation.

RESULTS
Aggregated Clusters
A total of 2,330 TB cases were reported to Los Angeles County Department of Public Health during 2015–2018 (Figure 3). Of these, 83% (n = 1,930) were culture-confirmed and assigned a genotype; 492 (25%) of these cases were clustered and further investigated. Molecular surveillance in California and the cluster investigations conducted by Los Angeles County identified an additional 492 cases among patients who had either epidemiologic or genotypic links to the patients identified in Los Angeles County and either resided outside of the county, were reported before 2015 or after 2018, or both. Of the 984 total TB cases investigated, presumed source cases were identified for 12% (n = 122). When we restricted analyses to only those cases with high-quality sequences and those for which the results of WGS analysis were not available before the source case was designated (i.e., source case determinations that were not influenced by WGS results), 59 source–secondary case pairs were available for analysis.

One hundred six cases comprised the 59 source–secondary case pairs (9 cases were designated as the presumed source for >1 secondary case and 3 cases were both a secondary case and a presumed source case). These patients were predominantly male (66%; n = 62), Hispanic (72%; n = 76), and non-US–born (66%; n = 70) (Table 1). The majority of cases had been diagnosed in Los Angeles County (97%; n = 103). The median size of genotype-matched clusters to which cases belonged was 5 (interquartile range: 3–8). Twenty-six percent (n = 28) of patients reported substance use (drug or excess alcohol use), and 7% (n = 7) reported experiencing homelessness during the year before TB diagnosis. The proportions of patients with HIV coinfection or other reported potential causes of immunocompromise were low (∼5%), except for diabetes mellitus (19%; n = 20). Previous TB disease diagnoses were uncommon (2%; n = 2). TB patients included in the final analytic data set of source–secondary case pairs were similar to all patients who had undergone investigation, but were on average younger, belonged to smaller clusters, were more likely to be of Hispanic ethnicity, and were less likely to have been homeless during the year before their TB diagnosis (Table 1).

The epidemiologic links between the 59 source–secondary case pairs were usually classified as definite (93%; n = 55) (Table 2). Thirty-seven (63%) pairs were between named contacts; 15 (25%) were linked through a shared location; 6 (10%) were among family members; and 1 (2%) had shared...
contacts in a social network. The estimated median TB infectious periods of source and secondary patients were 202 and 144 days, respectively.

*Mtb* isolates from the 59 case pairs were predominantly Euro-American lineage (75%) but included East Asian lineage (12%) and Indo-Oceanic lineage (14%) as well. Three case pairs from different genotype-matched clusters had large SNP differences that were inconsistent with a direct transmission event (16, 27, and 58 SNPs for case pairs with modified case-pair intervals of 7.5 months, 1.4 years, and 6.2 years, respectively) and were excluded from the analysis. Among the remaining pairs, pairwise SNP differences ranged from 0 to 10 (median: 1; IQR: 0–2). Case-pair intervals ranged from 0 to 14.5 years (median: 304 days; IQR: 74–935 days), and modified case-pair intervals ranged from 0 to 15.1 years (median: 197 days; IQR: 19–827 days) (Appendix Figure 1). Four case pairs with modified case-pair intervals of ≤2 years had isolates >5 SNPs apart. Although these cases had definite epidemiologic links, further inspection of the direction of genetic change indicated that isolates in all 4 of these case pairs diverged in different directions from a hypothetical MRCA. The same was true for 4 of the 5 case pairs with modified case-pair intervals of >2 years and isolates >5 SNPs apart.

The trend between the modified case-pair interval and SNP differences was not linear (Appendix Figure 2A), and a small difference occurred in the pairwise SNP difference between case pairs with a modified case-pair interval of ≤2 years (i.e., recent transmission) (median: 0 SNPs; IQR: 0–1 SNPs), and those with an interval of >2 years (median: 1.5 SNPs; IQR: 0–5.5 SNPs) (Figure 4). The functions we fit to these data both showed low $R^2$ values (≤0.10), indicating poor fit of both linear and piecewise linear models (Appendix Figure 2). Based on the distribution of time data, we defined relatively longer modified case-pair intervals as >3 years. Notably, isolates from multiple case pairs with longer modified case-pair intervals (>3 years)
TABLE 1 | Demographic, molecular, and clinical characteristics of patients in the analytic data set of genotype-matched TB source-secondary case pairs vs. other investigated cases in Los Angeles County, California, 2015–2018.

| Characteristic                          | Cases included in case pairs $(n = 106)$ no. (%) | Other investigated cases $(n = 878)$ no. (%) |
|----------------------------------------|--------------------------------------------------|--------------------------------------------|
| Demographic characteristics            |                                                  |                                            |
| Sex                                    |                                                  |                                            |
| Male                                   | 66 (62)                                          | 581 (66)                                   |
| Female                                 | 39 (37)                                          | 287 (33)                                   |
| Unknown/missing                         | 1 (1)                                            | 10 (1)                                     |
| Median age (yrs) (IQR)                 | 39 (22–47)                                       | 50 (34–63)                                 |
| Race/ethnicitya                        |                                                  |                                            |
| Asian                                  | 21 (20)                                          | 292 (33)                                   |
| Black/African American                 | 5 (5)                                            | 110 (13)                                   |
| Hispanic/Latino                        | 76 (72)                                          | 428 (49)                                   |
| White                                  | 3 (3)                                            | 35 (4)                                     |
| Unknown/missing                         | 1 (1)                                            | 10 (1)                                     |
| Birthplaceb                            |                                                  |                                            |
| US-born                                 | 35 (33)                                          | 250 (28)                                   |
| Non-US–born                            | 70 (66)                                          | 613 (70)                                   |
| Unknown/missing                         | 1 (1)                                            | 15 (2)                                     |
| TB diagnosis location                   |                                                  |                                            |
| In Los Angeles County                  | 103 (97)                                         | 852 (97)                                   |
| Outside Los Angeles County             | 3 (3)                                            | 26 (3)                                     |
| Molecular characteristics              |                                                  |                                            |
| Culture status                         |                                                  |                                            |
| Positive                               | 105 (99)                                         | 843 (96)                                   |
| Negative                               | 0                                                | 14 (2)                                     |
| No results reported                    | 1 (1)                                            | 21 (2)                                     |
| Number of genotype-matched clusters    | 44                                               | 178                                        |
| Median number of cases (IQR)           | 5 (3–8)                                          | 7 (4–12)                                   |
| Minimum number of cases                | 2                                                | 2                                          |
| Maximum number of cases                | 14                                               | 38                                         |
| Social characteristics                 |                                                  |                                            |
| Any substance use                      | 28 (26)                                          | 182 (21)                                   |
| Excess alcohol use during previous yearc| 16 (15)                                          | 137 (75)                                   |
| Injection drug use during previous yearc| 3 (11)                                           | 15 (8)                                     |
| Non-injection drug use during previous yearc| 17 (61)                                         | 86 (47)                                    |
| No reported history of substance use during previous year | 75 (71) | 650 (74) |
| Unknown/missing                         | 3 (3)                                            | 46 (5)                                     |
| Homelessness                           |                                                  |                                            |
| Homeless during the year before diagnosis | 7 (7) | 120 (14) |
| No known history of homelessness during the year before diagnosis | 98 (92) | 744 (85) |
| Unknown/missing                         | 1 (1)                                            | 14 (2)                                     |
| Incarceration                          |                                                  |                                            |
| TB diagnosed while patient was incarcerated | 0 | 24 (3) |
| TB diagnosed while patient was not incarcerated | 105 (99) | 844 (96) |
| Unknown/missing                         | 1 (1)                                            | 10 (1)                                     |

(Continued)

TABLE 1 | Continued

| Characteristic                          | Cases included in case pairs $(n = 106)$ no. (%) | Other investigated cases $(n = 878)$ no. (%) |
|----------------------------------------|--------------------------------------------------|--------------------------------------------|
| Clinical characteristics               |                                                  |                                            |
| HIV testing                            |                                                  |                                            |
| Positive                               | 1 (1)                                            | 30 (3)                                     |
| Negative                               | 88 (83)                                          | 656 (75)                                   |
| Not offered                            | 7 (7)                                            | 66 (8)                                     |
| Refused                                | 0 (0)                                            | 7 (1)                                      |
| Unknown/missing                         | 10 (9)                                           | 119 (14)                                   |
| Other                                  |                                                  |                                            |
| Immunosuppression other than HIV       | 0                                                | 45 (5)                                     |
| Tumor necrosis factor-α antagonist     | 0                                                | 8 (1)                                      |
| therapy                                |                                                  |                                            |
| Post-organ transplantation             | 0                                                | 7 (1)                                      |
| Diabetes mellitus                      | 20 (19)                                          | 231 (26)                                   |
| End-stage renal disease                | 1 (1)                                            | 26 (3)                                     |
| Any first line-drug resistance         | 4 (4)                                            | 107 (12)                                   |

IQR, interquartile range.

aHispanic/Latino includes all persons with Hispanic/Latino ethnicity. Other categories include persons with non-Hispanic/Latino ethnicity and the respective race.

bUS-born is based on eligibility for citizenship at birth and includes people born overseas to parents who are US citizens.

cFrequencies of patients with excess alcohol use and injection and non-injection drug use reported during the previous year are tabulated among the subset of patients reporting any substance use. These categories of substance use are not mutually exclusive (i.e., a patient with multiple substance use may be counted multiple times).

were approximately identical to those of the source patients on the basis of sequencing. The trends between case-pair interval and SNP distance were similar to those between modified case-pair interval and SNP distance (data not shown).

**Single-Cluster**

The SNP distances for the 10 genotype-matched cases in California are illustrated in a phylogenetic tree (Figure 5); 6 isolates are from patients with definite or possible epidemiologic links to a patient with infectious TB in a California school (Case X). Case X was diagnosed in 2001 and is the most likely source for 5 other cases in that cluster. Five presumptive secondary cases were diagnosed in 2008 (1 case), 2010 (1 case), 2013 (2 cases), and 2017 (1 case). Four of these patients had clear epidemiologic links to the 2001 source patient established through a 2013 cluster investigation. Duration of latent infection appears to be related to SNP differences; the *Mtb* isolate from the case diagnosed in 2008 had a pairwise difference of 2 SNPs relative to the source patient’s isolate; the 2010 isolate was 3 pairwise SNPs from the source patient’s isolate; and the isolates from 2013 were 4 and 7 SNPs different from the source patient’s isolate, respectively. However, the isolate from the case diagnosed most recently, in 2017, was most closely related genetically to the index Case X (1 SNP). Of note, the possible epidemiologic link between these 2 patients involved a connection to the same neighborhood but no known direct contact, allowing for the possibility that another infectious
case in the cluster might have been the source for the 2017 case. The 4 other isolates were from cases diagnosed during the same period but had large SNP differences (range: 84–174 SNPs) and therefore were ruled out as being part of the transmission chain involving Case X.

**DISCUSSION**

Our analysis of 59 source–secondary case pairs derived from a diverse set of clustered cases investigated in Los Angeles County did not indicate a linear association between SNP distance and modified case-pair interval, a proxy for duration of latent *Mtb* infection and TB disease. Efforts to fit a piecewise linear function to these data also were unsuccessful, which underscores the lack of a clear association between modified case-pair intervals and SNP difference. Furthermore, the range of pairwise SNP distances observed for cases with modified case-pair intervals >2 years (0–10 SNPs) was the same as that for cases with intervals ≤2 years, indicating that SNP distance alone is insufficient for differentiating between cases attributable to recent transmission and cases attributable to reactivation from transmission that occurred during the remote past. Although TB programs might consider cases with isolates that are >5 SNPs apart unlikely to be related by recent transmission, 4 case pairs with definite epidemiologic links and modified case-pair intervals of ≤2 years had isolates >5 SNPs apart. However, the direction of genetic change was inconsistent with direct transmission. Examination of the direction of genetic change can provide additional information beyond an absolute SNP distance and modified case-pair interval, a proxy for duration of latent infection. Therefore, SNP differences between the presumed source case. Separately, we determined that longer presumed infection periods were inconsistently associated with larger SNP differences on the basis of detailed examination of a single, well-characterized cluster of TB cases in California with a nationally uncommon genotype. We observed cases attributable to reactivation of latent infection that were epidemiologically linked to a source case in the remote past and had isolates with few SNP differences relative to this presumed source’s isolate. These analyses indicate that no universal rule can be applied consistently to genomic data from a TB cluster to determine the time when specific patients acquired their *Mtb* infection, which implies that WGS alone cannot be used to determine definitively that a case is attributable to recent transmission.

Although a constant rate of mutation during latent infection similar to that during disease might have indicated that cases with longer latent periods would accumulate more mutations than those with shorter latent periods, this is not supported by our data or uniformly by published studies. We reviewed 4 epidemiologic and 2 laboratory (animal model) studies that estimated the mutation rate of *Mtb* during latent infection ([Appendix Table 1](#)). Two epidemiologic studies reported a similar mutation rate during latent infection and disease (18, 19), and two others reported a lower rate during latent infection (20, 21). The two laboratory studies reported either a similar mutation rate between latent infection and disease among non-human primates or that *Mtb* replicates throughout the course of chronic infection of mice (22, 23). Considerable uncertainty remains regarding the mutation rate of *Mtb* during latent infection. While robust genomic and epidemiologic data from TB case investigations can provide some insight into the expected number of genetic differences between the *Mtb* isolates of patients linked through transmission, they are limited by the fact that it is difficult to infer the duration of latent infection.

Bacterial WGS has revolutionized molecular characterization of *Mtb* (24). Compared with previous strain-typing methods, which examine <1% of the *Mtb* genome, analyses of WGS data characterize >90% of the genome at the level of individual base-pairs, enabling measurement of fine-scale variation approximately genome-wide. Employing WGS for identifying evidence of recent TB transmission is often more discriminatory than traditional genotyping methods: whereas conventional genotyping can indicate that two isolates are a match on the basis of a small part of the genome, WGS can reveal additional sequence diversity that can be epidemiologically relevant (7). However, despite these technologic advances, this report illustrates why phylogenetic analyses should be interpreted alongside available clinical and epidemiologic information for accurately characterizing clusters of TB cases and guiding further control efforts. Our findings largely support studies that have demonstrated the importance of integrating epidemiologic and genomic data to make inferences about TB transmission events in settings of low TB incidence (13, 25, 26). To facilitate this data integration, DTBE has developed a logically inferred TB transmission algorithm (LITT) (27). A LITT user’s manual, training (mock) data sets, training presentation, input file templates, and all code written in R (28) are available at

**TABLE 2** | Epidemiologic and infectiousness characteristics of genotype-matched TB source–secondary case pairs in Los Angeles County, California, 2015–2018, included in the analytic data set.

| Characteristic                          | Case pairs n = 59 |
|----------------------------------------|-------------------|
| Strength of epidemiologic link          |                   |
| Definite                               | 55 (93)           |
| Probable                               | 4 (7)             |
| Possible                               | 0 (0)             |
| Type of epidemiologic link             |                   |
| Named contact                          | 37 (63)           |
| Shared location                        | 15 (25)           |
| Family member                          | 6 (10)            |
| Shared contact(s) or social network    | 1 (2)             |
| Infectiousness of presumed source case |                   |
| Pulmonary, smear-positive or cavitary  | 46 (96)           |
| Pulmonary, smear-negative and non-cavitary | 2 (4)         |
| Median TB infectious period of presumed source patients (days) (IQR) | 202 (132–287) |
| Median TB infectious period of secondary patients (days) (IQR) | 144 (121–186) |

IQR, Interquartile range.

*See Appendix Table 2 for definitions of definite and probable epidemiologic links.*
Our findings support the use of tools such as LITT, which allow for systematic integration and interpretation of genomic and epidemiologic data to guide outbreak investigation in the U.S.

In the United States, investigation of transmission chains is facilitated by a relatively low TB incidence, routine contact investigations, and a well-established molecular surveillance system. National surveillance data indicate that the majority of (>80%) TB cases were attributable to reactivation of infection acquired >2 years prior (remote transmission); while many of these reactivation cases are likely to have resulted from infection acquired outside of the United States, some cases are probably the result of remote transmission within the United States (28, 29). However, local TB programs still spend substantial resources investigating TB clusters that might involve recent transmission. Among certain populations, suspected cases of recent transmission share Mtb strains that have persistently circulated in the same area over many years, leading to large clusters of common genotypes with transmission links that are difficult to resolve, even with WGS. WGS can reveal that these clustered isolates are all closely related with few (≤5) SNP differences, placing the burden on public health officials to determine through epidemiologic investigation if these similarities are attributable to recent transmission or reactivation of a longstanding latent infection with the same, epidemiologically entrenched strain. In these cases, resource allocations for investigation might need to be prioritized. For example, referring back to contact investigation records of past TB cases might identify previously unrecognized epidemiologic links or a contact who was not fully evaluated or treated to prevent progression to disease, allowing the TB program to conclude a recent TB case is attributable to reactivation of latent infection. This review process can be challenging and time-consuming if records are incomplete or unavailable. Conversely, occurrence of multiple cases in a short timespan might indicate recent transmission rather than concomitant reactivations of TB disease. In that scenario, contact investigations for current cases might be expanded, or cluster investigations to identify epidemiologic links among recent cases might be initiated. WGS data can serve to guide these decisions, but our analysis reveals that an overreliance on these data might not serve prevention efforts well. Thus, a better understanding of the expected rate of genetic change during latent Mtb infection can help guide public health practitioners in allocating resources more effectively.

Our study has multiple limitations. First, epidemiologic studies that aim to understand mutation rates during Mtb infection are inherently limited by the inability to sample Mtb from latently infected persons. We used the genetic profile of Mtb from the source case as a proxy for the sequence upon infection of the secondary case. In other words, we assumed that the source Mtb sequence did not change and all mutations occurred in the secondary case. This assumption may be plausible given that we generally observed that Mtb isolates from presumed source cases did not have mutations that were absent from secondary cases’ isolates. However, it is unclear to what extent Mtb bacteria present in sputum sampled for genotyping accurately represent either the clonal population of bacteria in the lungs or the genetic makeup of bacteria transmitted to secondary cases. Advanced tools for detecting minor genomic variants, including deep sequencing techniques, might prove important in

![FIGURE 4](https://github.com/CDCgov/TB_molecular_epidemiology)  
**FIGURE 4** Association between modified case-pair interval and pairwise single nucleotide polymorphism (SNP) difference between genotype-matched source–secondary case pairs in Los Angeles County, California, 2015–2018. a. The modified case-pair interval is defined as the time between the estimated midpoint of the source patient’s TB infectious period and the sample collection date of the secondary patient. Each dot corresponds to a source–secondary case pair. **(A)** Scatter plot of modified case-pair interval, in years, against pairwise SNP distance. **(B)** Pairwise SNP differences of case pairs with modified case-pair intervals defined as recent transmission (during the previous 2 years) or reactivation (transmission occurred >2 years ago).
understanding the clonal variation present during infection and disease, which can be useful for defining transmission events (30–32). Because this is typically unavailable at a programmatic level, our analysis focuses on interpretation of WGS as implemented in the United States. Second, source–secondary case pairs might have been identified incorrectly or the case-pair intervals we calculated might be inaccurate. Source–secondary case pairs were identified by local public health as the most likely transmission pathway on the basis of available data; however, these links might not be correct especially if the true source case was undiagnosed or not genotyped. Cluster investigation practices were developing during 2015–2018, and resources applied to cluster investigations were inconsistent. Possibly, the investigators identified fewer case pairs during the initial years, which might have affected the completeness of the source–secondary case-pair data. Also, source determinations based on epidemiologic links are more likely to be made with cooperative patients and both epidemiologic and transmission links may be more frequently established for contacts identified in the recent past (e.g., recall bias). We used the modified case-pair interval between source–secondary case pairs as a proxy for the duration of latent infection of the secondary case. Diagnostic delays, estimated in a cohort study of 158 patients in Maryland to be >90 days for approximately half of TB cases, can lead to this period overestimating the duration of latent infection if the secondary patient in a pair did not seek care soon after progressing to TB disease (33). This can affect our results if diagnostic delays are attributable to pathologies that also affect disease progression (e.g., HIV infection status). Such factors have been reported to influence mutation rates during disease and likewise might influence mutation rates during latent infection (34). However, few HIV-positive cases existed in the clusters we analyzed, and any stratification by case characteristics was limited by our sample size. Third, the single-cluster investigation involving the school that we studied spanned 2001–2017; although genotyping of the presumed source case diagnosed in 2001 was performed retrospectively, universal genotyping of all TB cases in the United States with spoligotyping and 24-locus MIRU-VNTR did not begin until 2009. Thus, cases in this cluster that were involved in transmission might not have been genotyped and therefore not investigated. Fourth, accurately identifying presumed source cases among TB patients with nationally common genotypes is
difficult, given the relatively larger number of potential source cases. Consequently, the source–secondary pairs in our data are biased toward rarer genotypes, and mutation rates are known to vary by genotype. Fifth, we simplify the stages of Mtb infection into two discrete states, latent infection and TB disease. We acknowledge that this progression is better represented as a spectrum of disease, across which mutation rates can gradually change; this idea is supported by recent work that reviewed the epidemiologic evidence for discrete disease states and reported it to be lacking (35). Lastly, our results are not necessarily representative nationally given the focus on a single county where investigated cases had presumed source cases identified and WGS data were available but blinded to avoid biasing source case designations.

Implementation of routine WGS for TB cases in the United States will continue to provide more data for answering questions regarding how to combine and interpret epidemiologic and genomic data for guiding TB transmission control. Methods for integrating clinical and epidemiologic data with surveillance databases and phylogenetic analysis results can guide conclusions regarding both the likelihood of recent transmission and the likely directionality, settings, and social drivers of that transmission. Building such systems should be a future priority for providing local public health practitioners with better tools for monitoring and investigating TB transmission. The ability to more accurately interpret WGS in the context of other data sources can lead to a clearer understanding of TB epidemiology and ultimately improve TB prevention measures in such low-incidence settings as the United States.

**AUTHOR’S NOTE**

The findings and conclusions in this article are those of the authors and do not necessarily represent the views, opinions, or official position of the Centers for Disease Control and Prevention, the California Department of Public Health or the California Health and Human Services Agency.

**DATA AVAILABILITY STATEMENT**

The data analyzed in this study are subject to the following licenses/restrictions: Data were shared for the purposes of this project under a data use agreement and are only available via state and local public health department jurisdictions due to necessary patient privacy protections. Requests to access these datasets should be directed to Sarah Talarico, mzi4@cdc.gov.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Centers for Disease Control and Prevention Institutional Review Board and Los Angeles County Department of Public Health's Institutional Review Board. Written informed consent for participation was not provided by the participants' legal guardians/next of kin because this data was collected as a part of standard public health activities. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

KN: conceptualization, formal analysis, writing—original draft, and writing—review and editing. ST and CM: conceptualization, formal analysis, data curation, writing—original draft, and writing—review and editing. SP, MC, AC, WN, and TS: investigation, writing—review and editing. KR, LC, and JP: data curation and writing—review and editing. BS: conceptualization, writing—original draft, and writing—review and editing. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We thank the Los Angeles County Community Field, Clinic Service, and TB Control Program staff who provided direct patient care and case management services to all TB patients. Specifically, we thank Dr. Julie Higashi, the TB Control Program Director, and the Program’s Genotype Cluster Investigation and Assessment Unit (GCIA) for their diligent work engaging clients in documenting epidemiologic linkages among patients during the course of cluster investigations. GCIA staff include Bezaleel Gebru, Jamée M. Gomez, and Kim Do (CDC Public Health Advisors) and Nora Laine Fritz, Lauren Ruth Linde, Erika Alex, Erin L. Anderson, Sara Bemisarder, Mallory Aviva Perper, Stephen D. Passman, Johannah Hansen, Andrea Lomeli, Allison Dooolittle, and Vanessa Ruiz (CDC Public Health Associates) assigned to the team during 2015–2018. We also thank the current and former California Department of Public Health TB Control Branch staff who supported this work, including Dr. Jennifer Flood, Dr. Amit Chitnis, Kristiana Dhillon, Jocelyn Martinez, and Michael Joseph, as well as the local health department staff in California who provided epidemiologic data for the single cluster investigation.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2021.790544/full#supplementary-material

**REFERENCES**

1. Centers for Disease Control and Prevention. Prioritizing Tuberculosis Genotype Clusters for Further Investigation and Public Health Action. Atlanta, GA: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (2017).

2. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2019. Atlanta, GA: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (2019).

3. Talarico S, Silk BJ, Shaw T, Cilnis M. Whole-Genome Sequencing for Investigation of Recent TB Transmission in the United States: Current Uses and Future Plans. Atlanta, GA: Division
of Tuberculosis Elimination, Centers for Disease Control and Prevention.

4. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet. (2011) 43:482–6. doi: 10.1038/ng.811

5. Guerra-Assunção JA, Crampin AC, Houben RMG, Mzembe T, Mallard K, Coll F, et al. Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area. eLife. (2015) 4:e05166. doi: 10.7554/eLife.05166

6. Folkvardsen DB, Norman A, Andersen AB, Michael Rasmussen E, Jelsbak L, Lillembaek T. Genomic epidemiology of a major mycobacterium tuberculosis outbreak: retrospective cohort study in a low-incidence setting using sparse time-series sampling. J Infect Dis. (2017) 216:366–74. doi: 10.1093/infdis/jix298

7. Roetzer A, Diel R, Kohl TA, Rückert C, Nübel U, Blom J, et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med. (2013) 10:e1001387. doi: 10.1371/journal.pmed.1001387

8. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis from whole genome sequencing data. J Clin Microbiol. (2013) 51:110. doi: 10.1128/jcm.35.4.907-914.1997

9. Comin J, Chaure A, Cebollada A, Ibarz D, Viñuelas J, Vitoria M, et al. Investigation of a rapidly spreading tuberculosis outbreak using whole-genome sequencing. J Infect Genet Evol. (2020) 9:e91024. doi: 10.1371/journal.pone.091024

10. Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, et al. Mycobacterium tuberculosis mutation and transmission in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Inf Dis. (2013) 13:137–46. doi: 10.1016/S1473-3099(13)70273-9

11. Walker TM, Lalor MK, Broda A, Saldana Ortega L, Morgan M, Parker L, et al. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007–12, with whole pathogen genome sequences: an observational study. Lancet Respir Med. (2014) 2:285–92. doi: 10.1016/S2213-2600(14)70027-X

12. Bryant JM, Schürch AC, van Deutekom H, Harris SR, de Beer JL, de Jager V, et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis. (2013) 13:110. doi: 10.1186/1471-2334-13-110

13. Comin J, Chauré A, Cebollada A, Ibarz D, Viñuelas J, Vitoria M, et al. Investigation of a rapidly spreading tuberculosis outbreak using whole-genome sequencing. J Infect Genet Evol. (2020) 81:104184. doi: 10.1016/j.jigv.2020.104184

14. Stucki D, Ballif M, Bodmer T, Coscolla M, Maurer A-M, Droz S, et al. Tracking a tuberculosis outbreak over 21 years: strain-specific single-nucleotide polymorphism typing combined with targeted whole-genome sequencing. J Infect Dis. (2015) 211:1306–16. doi: 10.1093/infdis/jiv061

15. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper E, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during prolonged latent Mycobacterium tuberculosis infection in humans. Int J Med Microbiol. (2016) 306:580–5. doi: 10.1016/j.ijmm.2016.05.017

16. Yang Z, Rosenthal M, Rosenberg NA, Talarico S, Zhang C, Marrs C, et al. How dormant is Mycobacterium tuberculosis during latency? A study integrating genomics and molecular epidemiology. Infect Genet Evol. (2011) 11:1164–7. doi: 10.1016/j.meegid.2011.02.002

17. Colangeli R, Arcus VL, Cursons RT, Ruthe A, Karalus N, Coley K, et al. Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. PLoS ONE. (2014) 9:e91024. doi: 10.1371/journal.pone.091024

18. Gill WP, Hank NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med. (2009) 15:211–4. doi: 10.1038/nm.1915

19. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. (2013) 45:784–90. doi: 10.1038/ng.2656

20. Armstrong GL, MacCannell DR, Taylor J, Carletton HA, Neuhau EB, Bradbury RS, et al. Pathogen genomics in public health. N Engl J Med. (2019) 381:2569–80. doi: 10.1056/NEJMr1813907

21. Colangeli R, Arcus VL, Cursons RT, Ruthe A, Karalus N, Coley K, et al. Whole genome sequencing in cluster investigation of a multidrug-resistant tuberculosis outbreak. Eur Respir J. (2018) 51:1702313. doi: 10.1183/13993003.02313-2017

22. Guthrie JI, Strudwick L, Roberts B, Allen M, McFadzen J, Roth D, et al. Whole genome sequencing for improved understanding of Mycobacterium tuberculosis transmission in a remote circumpolar region. Epidemiol Infect. (2019) 147:1688. doi: 10.1017/S0950268819000670

23. Winglee K, McDaniel CJ, Linde L, Cammerer S, Cilnis M, Raz KM, et al. Logically Inferred Tuberculosis Transmission (LITT): a data integration algorithm to rank potential source cases. Front Public Health. (2021) 9:667337. doi: 10.3389/fpubh.2021.667337

24. Talwar A, Tsang CA, Price SF, Pratt RH, Walker WL, Schmit KM, et al. Tuberculosis – United States, 2018. Mortal Mortal Wkly Rep. (2019) 68:257–62. doi: 10.15585/mmwr.mm6811a2

25. Yuen CM, Kamermer JS, Marks K, Navin TR, France AM. Recent transmission of tuberculosis — United States, 2011–2014. PLoS ONE. (2016) 11:e0153728. doi: 10.1371/journal.pone.0153728

26. Worby CJ, Lipisich M, Hanage WP. Shared genomic variants: identification of transmission routes using pathogen deep-sequence data. Am J Epidemiol. (2017) 186:1209–16. doi: 10.1093/aje/kwx182

27. Nikolayevsky V, Niemann S, Anthony R, van Soolingen D, Tagliani E, Kødmøn C, et al. Role and value of whole genome sequencing in studying tuberculosis transmission. Clin Microbiol Infect. (2019) 25:1377–82. doi: 10.1016/j.cmi.2019.03.022

28. Séraphin MN, Norman A, Rasmussen EM, Gerace AM, Chibbaub CR, Rowlinson MC, et al. Direct transmission of whole-host Mycobacterium tuberculosis diversity to secondary cases can lead to variable between-host heterogeneity without de novo mutation: a genomic investigation. EBioMedicine. (2019) 47:293–300. doi: 10.1016/j.ebiom.2019.08.010

29. Colub JE, Bur S, Cronin WA, Gange S, Baruch N, Comstock GW, et al. Patient and health care system delays in pulmonary tuberculosis diagnosis in a low-incidence state. Int J Tuberc Lung Dis. (2005) 9:992–8.

30. Eldholm V, Rieux A, Monteserin J, Lopez JM, Palmero D, Lopez B, et al. Impact of HIV co-infection on the evolution and transmission of multidrug-resistant tuberculosis. Trends Ecol Evol. (2016) 5:306–13. doi: 10.1016/j.tree.16644

31. Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen VO, Andersen AB. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactionivation occurring decades after the initial infection. J Infect Dis. (2003) 188:1032–9. doi: 10.1086/378240

32. Lillebaek T, Norman A, Rasmussen EM, Marvigs RL, Folkvardsen DB, Anderssen AB, et al. Substantial molecular evolution and mutation rates in prolonged latent Mycobacterium tuberculosis infection in humans. Int J Med Microbiol. (2016) 306:580–5. doi: 10.1016/j.ijmm.2016.05.017
35. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. *BMJ*. (2018) 362:k2738. doi: 10.1136/bmj.k2738

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Nelson, Talarico, Poonja, McDaniel, Cilnis, Chang, Raz, Noboa, Cowan, Shaw, Posey and Silk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*